3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
8
Carcinoma, Merkel Cell
8
Neoplasms
7
Colorectal Neoplasms
7
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Neuroendocrine
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
avelumab
×
Clear all
NCT03512834
2018-07-11
ASAP
Dong-A University Hospital
Phase 2
Unknown
32 enrolled